NCT02054286View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

February 27, 2019

Conditions

HIV Infection

Interventions

BIOLOGICAL

THV01-1

Intramuscular injection of THV01-1 (week 0)

BIOLOGICAL

THV01-2

Intramuscular injection of THV01-2 (week 8)

BIOLOGICAL

Placebo

Intramuscular injection of placebo matching THV01-1 and THV01-2

Trial Locations (11)

6091

CHU Strasbourg, Strasbourg

21079

CHU Dijon, Dijon

31059

Hôpital Purpan, Toulouse

35033

CHU Rennes, Rennes

42055

Hôpital Nord, Saint-Etienne

65003

CHU Clermont-Ferrand, Clermont-Ferrand

69317

CHU Croix-Rousse, Lyon

75010

Hôpital Saint-Louis, Paris

75014

CIC Cochin-Pasteur; Hôpital Cochin, Paris

B-1000

CHU Saint-Pierre, Brussels

B-4000

CHU Liège, Liège

All Listed Sponsors

lead

Theravectys S.A.

INDUSTRY

NCT02054286 - Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART). | Biotech Hunter | Biotech Hunter